NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
NEKTAR THERAPEUTICS
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Aug 14, 2026
$36.64+0.86 (+2.40%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
NEKTAR THERAPEUTICS revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-cash royalty revenue related to the sales of future royalties | $10.13M | $21.81M | $11.49M | $11.18M | $10.46M | $16.24M | $15.73M | $16.79M | $15.51M | $18.06M | $18.17M | $15.83M | 100.0% | -9.3% |
| Product sales | – | $0 | $0 | $0 | $0 | $12.87M | $8.02M | $6.64M | $6.03M | $5.48M | $5.82M | $4.66M | – | – |
| License, collaboration and other revenue | – | $0 | $300.00K | $0 | $0 | $63.00K | $378.00K | $59.00K | $97.00K | $341.00K | $155.00K | $9.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Nektar Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.